[go: up one dir, main page]

RU2404771C3 - Комбинации, содержащие антимускариновые средства и бета-адренергические агонисты - Google Patents

Комбинации, содержащие антимускариновые средства и бета-адренергические агонисты Download PDF

Info

Publication number
RU2404771C3
RU2404771C3 RU2006147250A RU2006147250A RU2404771C3 RU 2404771 C3 RU2404771 C3 RU 2404771C3 RU 2006147250 A RU2006147250 A RU 2006147250A RU 2006147250 A RU2006147250 A RU 2006147250A RU 2404771 C3 RU2404771 C3 RU 2404771C3
Authority
RU
Russia
Prior art keywords
agonist
disease
antagonist
respiratory disease
muscarinic receptors
Prior art date
Application number
RU2006147250A
Other languages
English (en)
Other versions
RU2404771C2 (ru
RU2006147250A (ru
Original Assignee
Альмиралл С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34956036&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2404771(C3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Альмиралл С.А. filed Critical Альмиралл С.А.
Publication of RU2006147250A publication Critical patent/RU2006147250A/ru
Publication of RU2404771C2 publication Critical patent/RU2404771C2/ru
Application granted granted Critical
Publication of RU2404771C3 publication Critical patent/RU2404771C3/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Wrappers (AREA)

Claims (8)

1. Комбинация для лечения респираторного заболевания, содержащая (a) эффективное количество β2-агониста формотерола необязательно в форме фармакологически совместимых кислотно-аддитивных солей, и (b) эффективное количество антагониста мускариновых рецепторов М3, который представляет собой 3(R)-(2-гидрокси-2,2-дитиен-2-илацетокси)-1-(3-феноксипропил)-1-азонийбицикло[2.2.2]октан в форме соли с анионом X, который представляет собой фармацевтически приемлемый анион моно- или поливалентной кислоты.
2. Комбинация по п.1, где антагонист мускариновых рецепторов М3
(b) представляет собой бромид 3(R)-(2-гидрокси-2,2-дитиен-2-илацетокси)-1-(3-феноксипропил)-1-азонийбицикло[2.2.2]октана.
3. Комбинация по п.1 или 2, где β2-агонист представляет собой фумарат формотерола.
4. Комбинация по п.1 или 2, отличающаяся тем, что активные ингредиенты (а) и (b) образуют часть единой фармацевтической композиции.
5. Применение (а) β2-агониста, охарактеризованного в любом из пп.1 или 3, и (b) антагониста мускариновых рецепторов М3, охарактеризованного в п.1 или 2, для получения лекарственного средства для одновременного или совместного применения для лечения пациента, страдающего реагирующим на антагонизм М3 респираторным заболеванием.
6. Применение по п.5, где респираторное заболевание представляет собой хроническое обструктивное заболевание легких (COPD).
7. Продукт, содержащий (а) β2-агонист, охарактеризованный в любом из пп.1 или 3, и (b) антагонист мускариновых рецепторов М3, охарактеризованный в п.1 или 2, в виде комбинированного препарата для одновременного или совместного применения для лечения пациента, страдающего респираторным заболеванием, определенным в п.5 или 6, или восприимчивого к такому заболеванию.
8. Применение по п.5, где пациент страдает ранее присущим ему заболеванием сердца или состоянием, которое может быть ухудшено тахикардией.
RU2006147250A 2004-05-31 2005-05-31 Комбинации, содержащие антимускариновые средства и бета-адренергические агонисты RU2404771C3 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ESP200401312 2004-05-31
ES200401312A ES2257152B1 (es) 2004-05-31 2004-05-31 Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2010129940/15A Division RU2465902C2 (ru) 2004-05-31 2010-07-16 Комбинации, содержащие антимускариновые средства и бета-адренергические агонисты

Publications (3)

Publication Number Publication Date
RU2006147250A RU2006147250A (ru) 2008-07-20
RU2404771C2 RU2404771C2 (ru) 2010-11-27
RU2404771C3 true RU2404771C3 (ru) 2018-03-12

Family

ID=34956036

Family Applications (4)

Application Number Title Priority Date Filing Date
RU2006142331/15A RU2373935C2 (ru) 2004-05-31 2005-05-31 Комбинации, содержащие антимускариновые агенты и ингибиторы pde4
RU2006147250A RU2404771C3 (ru) 2004-05-31 2005-05-31 Комбинации, содержащие антимускариновые средства и бета-адренергические агонисты
RU2006147268/15A RU2385721C2 (ru) 2004-05-31 2005-05-31 Комбинации, включающие антимускариновые агенты и кортикостероиды
RU2010129940/15A RU2465902C2 (ru) 2004-05-31 2010-07-16 Комбинации, содержащие антимускариновые средства и бета-адренергические агонисты

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RU2006142331/15A RU2373935C2 (ru) 2004-05-31 2005-05-31 Комбинации, содержащие антимускариновые агенты и ингибиторы pde4

Family Applications After (2)

Application Number Title Priority Date Filing Date
RU2006147268/15A RU2385721C2 (ru) 2004-05-31 2005-05-31 Комбинации, включающие антимускариновые агенты и кортикостероиды
RU2010129940/15A RU2465902C2 (ru) 2004-05-31 2010-07-16 Комбинации, содержащие антимускариновые средства и бета-адренергические агонисты

Country Status (45)

Country Link
US (41) US20080051378A1 (ru)
EP (14) EP2210613A1 (ru)
JP (8) JP5032984B2 (ru)
KR (3) KR20130027586A (ru)
CN (8) CN102755321B (ru)
AR (1) AR049066A1 (ru)
AT (3) ATE417627T1 (ru)
AU (3) AU2005247107B2 (ru)
BE (1) BE1016608A5 (ru)
BR (6) BRPI0511662B8 (ru)
CA (3) CA2568566C (ru)
CH (1) CH696962A5 (ru)
CL (1) CL2011000607A1 (ru)
CY (7) CY1108885T1 (ru)
DE (3) DE602005013220D1 (ru)
DK (5) DK1891973T3 (ru)
EC (6) ECSP067034A (ru)
ES (7) ES2257152B1 (ru)
FR (2) FR2870744B1 (ru)
GB (1) GB2419819B (ru)
GR (1) GR1006045B (ru)
HR (4) HRP20090215T4 (ru)
HU (2) HUP0600139A3 (ru)
IL (3) IL179684A (ru)
IT (1) ITMI20051021A1 (ru)
LT (1) LTC1763368I2 (ru)
LU (1) LU91214B1 (ru)
MC (1) MC200083A1 (ru)
ME (4) ME01680B (ru)
MX (3) MXPA06013847A (ru)
MY (1) MY142095A (ru)
NL (2) NL1029151C2 (ru)
NO (7) NO20065477L (ru)
NZ (3) NZ544539A (ru)
PE (3) PE20081650A1 (ru)
PL (6) PL1765404T3 (ru)
PT (4) PT2292267E (ru)
RS (4) RS53529B1 (ru)
RU (4) RU2373935C2 (ru)
SI (5) SI1891973T1 (ru)
TW (1) TWI404530B (ru)
UA (6) UA89184C2 (ru)
UY (1) UY28933A1 (ru)
WO (3) WO2005115462A1 (ru)
ZA (6) ZA200600261B (ru)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100471016B1 (ko) * 1996-08-07 2005-07-12 스미또모 가가꾸 가부시키가이샤 살충성에어로졸조성물및이를제조하기위한살충조성물
ES2165768B1 (es) * 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
EP1651236A1 (en) * 2003-07-29 2006-05-03 Boehringer Ingelheim International GmbH Combination of an anticholinergic and a steroid and its use to treat respiratory disorders by inhalation
US20050026948A1 (en) * 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a betamimetic
ES2257152B1 (es) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
CA2569074C (en) * 2004-05-31 2012-12-18 Almirall Prodesfarma S.A. Combinations comprising antimuscarinic agents and pde4 inhibitors
EP1859804B1 (en) * 2005-02-10 2016-12-07 Oncolys BioPharma, Inc. Anticancer agent combination therapy
ES2330047T3 (es) * 2005-12-21 2009-12-03 MEDA PHARMA GMBH &amp; CO. KG Combinacion de r,r-glicopirrolato, rolipram y budesonida para el tratmiento de enfermedades inflamatorias.
US20090264388A1 (en) * 2006-02-22 2009-10-22 Valorisation Recherche Hscm, Limited Partnership Compounds and Methods of Treating Disorders Associated With Activation of Metachromatic Cells
US8007790B2 (en) * 2006-04-03 2011-08-30 Stowers Institute For Medical Research Methods for treating polycystic kidney disease (PKD) or other cyst forming diseases
TWI436761B (zh) * 2006-06-19 2014-05-11 Otsuka Pharma Co Ltd 使用噻唑衍生物之方法
ES2378281T3 (es) * 2006-07-05 2012-04-10 Nycomed Gmbh Combinación de atorvastatina con un inhibidor de fosfodiesterasa 4 para el tratamiento de neumopatías inflamatorias
JP2009543860A (ja) 2006-07-19 2009-12-10 アストラゼネカ・アクチエボラーグ 新規三環系スピロピペリジン化合物、それらの合成およびケモカイン受容体活性モジュレーターとしてのそれらの使用
ES2298049B1 (es) * 2006-07-21 2009-10-20 Laboratorios Almirall S.A. Procedimiento para fabricar bromuro de 3(r)-(2-hidroxi-2,2-ditien-2-ilacetoxi)-1-(3-fenoxipropil)-1-azoniabiciclo (2.2.2) octano.
UA98136C2 (ru) * 2007-02-21 2012-04-25 Алмиралл, С.А. Применение аклидиния для лечения респираторных заболеваний
CA2608561A1 (en) * 2007-10-29 2009-04-29 Carl Paluszkiewicz Motorcycle wind deflector accessory support
EP2080523A1 (en) * 2008-01-15 2009-07-22 CHIESI FARMACEUTICI S.p.A. Compositions comprising an antimuscarinic and a long-acting beta-agonist
EP2080508A1 (en) * 2008-01-15 2009-07-22 CHIESI FARMACEUTICI S.p.A. Dry powder formulation comprising an anticholinergic drug
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2280708A1 (en) * 2008-03-14 2011-02-09 Otsuka Pharmaceutical Co., Ltd. Mmp-2 and/or mmp-9 inhibitor
AU2009252938B2 (en) 2008-05-27 2012-04-26 Astrazeneca Ab Phenoxypyridinylamide derivatives and their use in the treatment of PDE4 mediated disease states
GB0814729D0 (en) * 2008-08-12 2008-09-17 Argenta Discovery Ltd New combination
EP2156847A1 (en) * 2008-08-19 2010-02-24 Sanofi-Aventis New combination of active ingredients containing an alpha1-antagonist and a PDE 4 inhibitor.
PT3578169T (pt) 2009-02-26 2024-07-29 Glaxo Group Ltd Formulações farmacêuticas compreendendo 4-{(1r)-2-[(2,6- diclorobenzil)oxi]etoxi}hexil)amino]-1-hidroxietil}-2- (hidroximetil)fenol
US10265311B2 (en) 2009-07-22 2019-04-23 PureTech Health LLC Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
EP3646870A1 (en) 2009-07-22 2020-05-06 Puretech Health LLC Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
PE20171256A1 (es) 2010-08-03 2017-08-28 Chiesi Farm Spa Formulacion de polvo seco que comprende un inhibidor de fosfodiesterasa
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
CN103562198B (zh) 2011-06-10 2016-08-24 奇斯药制品公司 具有毒蕈碱受体拮抗剂和β2肾上腺素能受体激动剂活性的化合物
WO2012168349A1 (en) 2011-06-10 2012-12-13 Chiesi Farmaceutici S.P.A. Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
RS63759B1 (sr) * 2012-01-25 2022-12-30 Chiesi Farm Spa Formulacija suvog praha koja sadrži kortikosteroid i beta-adrenergik, za primenu inhalacijom
CN104470503A (zh) 2012-04-13 2015-03-25 葛兰素史克知识产权开发有限公司 聚集粒子
US9156833B2 (en) 2012-07-16 2015-10-13 Barry University, Inc. Bitopic muscarinic agonists and antagonists and methods of synthesis and use thereof
SG11201504318UA (en) 2012-12-06 2015-07-30 Chiesi Farma Spa Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
KR102156441B1 (ko) * 2012-12-06 2020-09-17 키에시 파르마슈티시 엣스. 피. 에이. 무스카린성 수용체 길항제 및 베타2 아드레날린성 수용체 효능제 활성을 가지는 화합물
GB201222679D0 (en) 2012-12-17 2013-01-30 Glaxo Group Ltd Pharmaceutical combination products
HRP20180684T1 (hr) * 2013-03-15 2018-06-01 Verona Pharma Plc Kombinacija lijekova
WO2015054101A1 (en) * 2013-10-09 2015-04-16 Icon Medical Corp. Improved metal alloy for medical devices
KR102250783B1 (ko) 2013-11-15 2021-05-11 퍼포먼스 폴리아미드 에스에이에스 금속 코팅용 폴리아미드 조성물 및 그것으로 코팅된 금속 성분
RU2685706C2 (ru) * 2014-01-10 2019-04-23 Эфиммьюн Лимитед Фармацевтические композиции, содержащие 15-гэпк, и способы лечения астмы и заболеваний легких с их применением
TWI703138B (zh) 2015-02-12 2020-09-01 義大利商吉斯藥品公司 具有蕈毒鹼受體拮抗劑及β２腎上腺素受體促效劑活性之化合物
AR104828A1 (es) 2015-06-01 2017-08-16 Chiesi Farm Spa COMPUESTOS CON ACTIVIDAD ANTAGONISTA DE LOS RECEPTORES MUSCARÍNICOS Y ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENÉRGICO
WO2017093208A1 (en) 2015-12-03 2017-06-08 Chiesi Farmaceutici S.P.A. Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
EP3400214B1 (en) * 2016-01-08 2024-03-13 Theron Pharmaceuticals, Inc. Dry powder inhaler compositions of 7-azoniabicyclo[2.2.1]heptane derivatives
WO2018011090A1 (en) 2016-07-13 2018-01-18 Chiesi Farmaceutici S.P.A. Hydroxyquinolinone compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
EP3625232B1 (en) 2017-05-19 2021-06-23 Council of Scientific and Industrial Research Substituted methanopyrido [2, 1-a]isoindolones as machr modulators for treating various associated pathophysiological conditions and process for preparation thereof
WO2019147824A1 (en) 2018-01-26 2019-08-01 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
EP3856182B1 (en) 2018-09-28 2025-12-24 Karuna Therapeutics, Inc. Compositions and methods for treating disorders ameliorated by muscarnic receptor activation
US20220249814A1 (en) 2018-11-19 2022-08-11 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
EP4309722A3 (en) 2019-12-13 2024-08-07 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
IT202000006442A1 (it) 2020-03-27 2021-09-27 Genetic S P A Budesonide 21-phosphate salts and pharmaceutical compositions containing the same
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases
US11504332B2 (en) * 2021-03-23 2022-11-22 Vk Research Associates Inc. Phosphodiesterase-4 inhibitor combinations, methods of making, and methods of use thereof
US20240270701A1 (en) * 2021-09-23 2024-08-15 Curasen Therapeutics, Inc. Beta adrenergic agonist and methods of using the same

Family Cites Families (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1219606A (en) * 1968-07-15 1971-01-20 Rech S Et D Applic Scient Soge Quinuclidinol derivatives and preparation thereof
FR2414044A1 (fr) * 1978-01-10 1979-08-03 Pharmindustrie Nouveaux derives d'aza-1 bicyclo(2,2,2) octane, utilisables comme medicaments
IT7920688U1 (it) 1979-02-05 1980-08-05 Chiesi Paolo Inalatore per sostanze medicamentose pulverulente, con combinata funzione di dosatore
ATE23272T1 (de) 1981-07-08 1986-11-15 Draco Ab Pulverinhalator.
FR2539135B1 (fr) * 1983-01-11 1986-02-28 Essilor Int Hydrogels de polyurethane et procede de fabrication
US4570630A (en) 1983-08-03 1986-02-18 Miles Laboratories, Inc. Medicament inhalation device
GB8334494D0 (en) * 1983-12-24 1984-02-01 Tanabe Seiyaku Co Carbostyril derivatives
FI69963C (fi) 1984-10-04 1986-09-12 Orion Yhtymae Oy Doseringsanordning
US4675326A (en) * 1985-05-08 1987-06-23 Gabriel Amitai Bisquaternary antidotes
US4843074A (en) * 1988-05-17 1989-06-27 Marion Laboratories, Inc. 1-azabicyclo[2.2.2]octan-3-yl 2-aryl-3-azacyclo-2-hydroxypropionates and their quaternary salts
DE3927170A1 (de) * 1989-08-17 1991-02-21 Boehringer Ingelheim Kg Inhalator
US5290815A (en) * 1989-09-07 1994-03-01 Glaxo Group Limited Treatment of inflammation and allergy
US5610163A (en) * 1989-09-16 1997-03-11 Boehringer Ingelheim Gmbh Esters of thienyl carboxylic acids and amino alcohols and their quaternization products
IT1237118B (it) 1989-10-27 1993-05-18 Miat Spa Inalatore multidose per farmaci in polvere.
US5201308A (en) 1990-02-14 1993-04-13 Newhouse Michael T Powder inhaler
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
SG45171A1 (en) 1990-03-21 1998-01-16 Boehringer Ingelheim Int Atomising devices and methods
GB9015522D0 (en) 1990-07-13 1990-08-29 Braithwaite Philip W Inhaler
WO1992003175A1 (en) 1990-08-11 1992-03-05 Fisons Plc Inhalation device
DE4027391A1 (de) 1990-08-30 1992-03-12 Boehringer Ingelheim Kg Treibgasfreies inhalationsgeraet
US5507281A (en) * 1990-08-30 1996-04-16 Boehringer Ingelheim Kg Device for initiating a mechanical switching operation in synchronism with the breathing
EP0640354B1 (en) 1990-09-26 2001-12-05 Pharmachemie B.V. Whirl chamber powder inhaler
GB9026025D0 (en) * 1990-11-29 1991-01-16 Boehringer Ingelheim Kg Inhalation device
US5290539A (en) * 1990-12-21 1994-03-01 Minnesota Mining And Manufacturing Company Device for delivering an aerosol
DE4108393A1 (de) * 1991-03-15 1992-09-17 Boehringer Ingelheim Kg Neue ester bi- und tricyclischer aminoalkohole, ihre herstellung und ihre verwendung in arzneimitteln
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
GB9202519D0 (en) * 1992-02-06 1992-03-25 Glaxo Group Ltd Medicaments
DE4239402A1 (de) 1992-11-24 1994-05-26 Bayer Ag Pulverinhalator
SG52459A1 (en) * 1992-12-09 1998-09-28 Boehringer Ingelheim Pharma Stabilized medicinal aerosol solution formulations
WO1994014492A2 (en) 1992-12-18 1994-07-07 Schering Corporation Inhaler for powdered medications
GB9412434D0 (en) * 1994-06-21 1994-08-10 Inmos Ltd Computer instruction compression
RO119116B1 (ro) 1995-04-14 2004-04-30 Glaxo Wellcome Inc. Inhalator pentru dozarea salmeterolului
ATE209518T1 (de) 1995-06-21 2001-12-15 Asta Medica Ag Arzneipulverkartusche mit integrierter dosiereinrichtung, sowie pulverinhalator
DE19528145A1 (de) * 1995-08-01 1997-02-06 Boehringer Ingelheim Kg Neue Arzneimittel und ihre Verwendung
DE19536902A1 (de) 1995-10-04 1997-04-10 Boehringer Ingelheim Int Vorrichtung zur Hochdruckerzeugung in einem Fluid in Miniaturausführung
US5846983A (en) * 1996-02-09 1998-12-08 Mayo Foundation For Medical Education And Research Colonic delivery of nicotine to treat inflammatory bowel disease
US6150415A (en) * 1996-08-13 2000-11-21 The Regents Of The University Of California Epoxide hydrolase complexes and methods therewith
US5885834A (en) * 1996-09-30 1999-03-23 Epstein; Paul M. Antisense oligodeoxynucleotide against phosphodiesterase
US6495167B2 (en) * 1997-03-20 2002-12-17 Schering Corporation Preparation of powder agglomerates
ITMI981671A1 (it) * 1998-07-21 2000-01-21 Zambon Spa Derivati ftalazinici inibitori della fosfodisterasi 4
CA2338680C (en) * 1998-08-04 2008-10-14 Jago Research Ag Medicinal aerosol formulations
DE19847968A1 (de) * 1998-10-17 2000-04-20 Boehringer Ingelheim Pharma Verschlußkappe und Behälter als Zweikammer-Kartusche für Vernebler zur Erzeugung von Aerosolen
GB9902689D0 (en) * 1999-02-08 1999-03-31 Novartis Ag Organic compounds
DE19921693A1 (de) * 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
GB9913083D0 (en) * 1999-06-04 1999-08-04 Novartis Ag Organic compounds
ES2165768B1 (es) * 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
US7214687B2 (en) * 1999-07-14 2007-05-08 Almirall Ag Quinuclidine derivatives and medicinal compositions containing the same
GB9928311D0 (en) * 1999-11-30 2000-01-26 Novartis Ag Organic compounds
US6410563B1 (en) * 1999-12-22 2002-06-25 Merck Frosst Canada & Co. Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
FR2803378B1 (fr) * 1999-12-29 2004-03-19 Valeo Climatisation Echangeur de chaleur a tubes a plusieurs canaux, en particulier pour vehicule automobile
US20030018061A1 (en) * 2000-01-28 2003-01-23 Kohei Ogawa Novel remedies with the use of beta 3 agonist
AU2001239550A1 (en) * 2000-03-23 2001-10-03 Takeda Chemical Industries Ltd. Furoisoquinoline derivatives, process for producing the same and use thereof
GB0008485D0 (en) * 2000-04-07 2000-05-24 Glaxo Group Ltd Pharmaceutical compositions
GB0009606D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Therapeutic combinations
GB0009583D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Respiratory formulations
GB0009592D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Respiratory combinations
GB0009605D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Medicaments
MXPA02011414A (es) * 2000-05-22 2003-06-06 Chiesi Farma Spa Formulaciones farmaceuticas en solucion estable para inhaladores presurizados con medicion de dosis.
US20020052312A1 (en) * 2000-05-30 2002-05-02 Reiss Theodore F. Combination therapy of chronic obstructive pulmonary disease using muscarinic receptor antagonists
WO2002000241A2 (en) * 2000-06-28 2002-01-03 Aventis Pharma S.A. Compositions and methods for regulating the cell cycle using a ki gene or polypeptide
US6852728B2 (en) * 2000-10-14 2005-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Anticholinergics, processes for preparing them, and pharmaceutical compositions containing them
US6706726B2 (en) * 2000-10-14 2004-03-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Anticholinergics which may be used as medicaments as well as processes for preparing them
AU2002210575A1 (en) 2000-10-31 2002-05-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel medicament compositions based on anticholinergics and corticosteroids
US6608054B2 (en) * 2001-03-20 2003-08-19 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics and endothelin antagonists
US20030158196A1 (en) * 2002-02-16 2003-08-21 Boehringer Ingelheim Pharma Gmbh Co. Kg Pharmaceutical compositions based on anticholinergics and EGFR kinase inhibitors
US20020183292A1 (en) * 2000-10-31 2002-12-05 Michel Pairet Pharmaceutical compositions based on anticholinergics and corticosteroids
US20020122773A1 (en) * 2000-12-20 2002-09-05 Michel Pairet Pharmaceutical compositions based on anticholinergics and dopamine agonists
US6620438B2 (en) * 2001-03-08 2003-09-16 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics and NK1-receptor antagonists
DE10062712A1 (de) * 2000-12-15 2002-06-20 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und Corticosteroiden
US20020151541A1 (en) * 2000-10-31 2002-10-17 Michel Pairet Pharmaceutical compositions containing tiotropium salts and antihistamines and their use
US20020137764A1 (en) * 2000-10-31 2002-09-26 Karin Drechsel Inhalable formulation of a solution containing a tiotropium salt
US20020193393A1 (en) * 2001-03-07 2002-12-19 Michel Pairet Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors
US7776315B2 (en) * 2000-10-31 2010-08-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and additional active ingredients
DE10056104A1 (de) * 2000-11-13 2002-05-23 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Tiotropiumsalzen und Salzen des Salmeterols
US20020193392A1 (en) * 2000-11-13 2002-12-19 Christel Schmelzer Pharmaceutical compositions based on tiotropium salts of salts of salmeterol
SI1353919T1 (sl) * 2000-12-28 2006-12-31 Almirall Prodesfarma Ag Novi derivati kinuklidina in medicinske zmesi, kijih vsebujejo.
US20020189610A1 (en) * 2001-02-01 2002-12-19 Karl-Heinz Bozung Pharmaceutical compositions containing an ipratropium salt and a betamimetic
US20020179087A1 (en) * 2001-02-01 2002-12-05 Karl-Heinz Bozung Pharmaceutical compositions containing an oxitropium salt and a betamimetic
US6667344B2 (en) * 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US20030216329A1 (en) * 2001-04-24 2003-11-20 Robinson Cynthia B. Composition, formulations & kit for treatment of respiratory & lung disease with dehydroepiandrosterone(s) steroid & an anti-muscarinic agent(s)
MXPA03010791A (es) * 2001-05-25 2004-03-02 Boehringer Ingelheim Pharma Combinacion de inhibidor de pde4 y tiotropio a sus derivados para tratamiento de enfermedades obstructivas de vias respiratorias y de otras enfermedades inflamatorias.
GB0115181D0 (en) * 2001-06-20 2001-08-15 Glaxo Group Ltd Novel use
US20030018019A1 (en) 2001-06-23 2003-01-23 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
DE10130371A1 (de) * 2001-06-23 2003-01-02 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika, Corticosteroiden und Betamimetika
US6919325B2 (en) * 2001-09-14 2005-07-19 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions containing tiotropium salts and low-solubility salmeterol salts
US6974803B2 (en) * 2001-12-06 2005-12-13 Pfizer Inc Pharmaceutical combination
US6790856B2 (en) * 2002-01-31 2004-09-14 Boehringer Ingelheim Pharma Kg Fluorenecarboxylic acid esters, process for the manufacture thereof, and use thereof as medicaments
GB0202635D0 (en) * 2002-02-05 2002-03-20 Glaxo Wellcome Mfg Pte Ltd Formulation containing novel anti-inflammatory androstane derivative
US6756508B2 (en) * 2002-03-04 2004-06-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Cinnamic acid salts, processes for their preparation, and their use as medicaments
US7094788B2 (en) * 2002-04-13 2006-08-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Esters of hydroxyl-substituted nitrogen heterocycles, processes for the preparation thereof as well as the use thereof as pharmaceutical compositions
ES2206021B1 (es) * 2002-04-16 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de pirrolidinio.
ES2195785B1 (es) 2002-05-16 2005-03-16 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
WO2003097098A1 (en) * 2002-05-17 2003-11-27 Novartis Ag Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic
MXPA04012410A (es) * 2002-06-12 2005-10-19 Epigenesis Pharmaceuticals Inc Composiciones, formulaciones y equipo para el tratamiento de enfermedades pulmonares y respiratorias con deshidroepiandrosteronas, esteroides y agentes antimuscarinicos.
MXPA05000434A (es) * 2002-07-08 2005-04-19 Ranbaxy Lab Ltd Derivados de hexano [3.1.0] azabiciclo 3,6-disustituido utiles como antagonistas de receptor muscarinico.
US20040058950A1 (en) * 2002-07-09 2004-03-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors
WO2004039968A1 (ja) * 2002-10-30 2004-05-13 Japan Science And Technology Agency 骨髄由来の不死化樹状細胞株
ES2211315B1 (es) 2002-11-12 2005-10-16 Almirall Prodesfarma, S.A. Nuevos compuestos triciclicos.
HRP20050572A2 (en) * 2002-11-27 2006-08-31 Altana Pharma Ag Pde4 and pde3/4 inhibitors for use in the treatment of cachexia
ES2211344B1 (es) 2002-12-26 2005-10-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
PE20040950A1 (es) * 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
DE10307759B3 (de) * 2003-02-19 2004-11-18 Schering Ag Trimere makrocyclisch substituierte Benzolderivate, deren Herstellung und Verwendung als Kontrastmittel sowie diese enthaltende pharmazeutische Mittel
US20040184995A1 (en) * 2003-03-17 2004-09-23 Yamanouchi Pharmaceutical Co., Ltd. Novel dry powder inhalation for lung-delivery and manufacturing method thereof
US20060189642A1 (en) * 2003-03-28 2006-08-24 Altana Pharma Ag Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases
ES2300755T3 (es) * 2003-03-28 2008-06-16 Nycomed Gmbh Combinacion sinergica que comprende roflumilast y un agente anticolinergico seleccionado de sales de tiotropio para el tratamiento de enfermedades respiratorias.
US20050026886A1 (en) * 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a PDE IV inhibitor
US20050026948A1 (en) * 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a betamimetic
KR20060052911A (ko) * 2003-07-29 2006-05-19 베링거 인겔하임 인터내셔날 게엠베하 베타흥분제와 항콜린제를 포함하는 흡입용 의약품
US20050026887A1 (en) * 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a steroid
US20050025718A1 (en) * 2003-07-31 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a betamimetic
EP1651224B1 (en) * 2003-07-31 2011-10-05 Boehringer Ingelheim International GmbH Medicaments for inhalation comprising an anticholinergic and a betamimetic
DE10347994A1 (de) * 2003-10-15 2005-06-16 Pari GmbH Spezialisten für effektive Inhalation Wässrige Aerosol-Zubereitung
ES2232306B1 (es) 2003-11-10 2006-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
CA2550841C (en) * 2004-02-06 2012-10-02 Meda Pharma Gmbh & Co. Kg Novel combination of anticholinergic and .beta. mimetics for the treatment of respiratory diseases
ES2413011T3 (es) * 2004-02-06 2013-07-15 Meda Pharma Gmbh & Co. Kg Combinación de anticolinérgicos y glucocorticoides para el tratamiento a largo plazo de asma y EPOC
WO2005074982A2 (en) * 2004-02-06 2005-08-18 Meda Pharma Gmbh & Co. Kg Combination of anticholinergics and inhibitors of phosphodiesterase type 4 for the treatment of respiratory diseases
US7375935B2 (en) * 2004-04-12 2008-05-20 Leviton Manufacturing Co., Inc. Ground fault circuit interrupter with enhanced radio frequency interference suppression
ES2257152B1 (es) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
US20060189551A1 (en) * 2004-10-04 2006-08-24 Duke University Combination therapies for fungal pathogens

Also Published As

Publication number Publication date
ES2505329T3 (es) 2014-10-09
ECSP067034A (es) 2006-12-29
RU2373935C2 (ru) 2009-11-27
PL1891973T3 (pl) 2010-11-30
IL179684A0 (en) 2007-05-15
EP2319538A3 (en) 2011-06-15
US20090093503A1 (en) 2009-04-09
ECSP067033A (es) 2006-12-29
AU2005247107A1 (en) 2005-12-08
CY1108902T1 (el) 2014-07-02
NO20065482L (no) 2006-12-22
US20070167489A1 (en) 2007-07-19
GR20050100269A (el) 2005-12-31
EP2138188A1 (en) 2009-12-30
WO2005115462A1 (en) 2005-12-08
BRPI0511656A (pt) 2008-01-02
MC200083A1 (fr) 2005-12-07
DE602005011803D1 (de) 2009-01-29
AU2005247103B2 (en) 2010-10-28
HRP20090107T3 (en) 2009-03-31
CN1960762A (zh) 2007-05-09
CY1115669T1 (el) 2017-01-25
NZ551667A (en) 2010-07-30
AU2005247107B2 (en) 2010-10-28
CN102755321A (zh) 2012-10-31
BRPI0511662B8 (pt) 2021-05-25
US20120302532A1 (en) 2012-11-29
CN102085373A (zh) 2011-06-08
US20080146603A1 (en) 2008-06-19
BRPI0511667A (pt) 2008-01-02
RS51386B (sr) 2011-02-28
ME01680B (me) 2010-08-31
US20100048616A1 (en) 2010-02-25
DK1765404T3 (da) 2009-03-16
CN102755321B (zh) 2015-07-15
SI1763368T1 (sl) 2009-08-31
EP1891973A1 (en) 2008-02-27
KR20070018105A (ko) 2007-02-13
PT2292267E (pt) 2014-10-15
NL1029151C2 (nl) 2006-06-22
CY1109139T1 (el) 2014-07-02
US20060189651A1 (en) 2006-08-24
RS50787B2 (sr) 2018-02-28
CN1960759B (zh) 2011-07-13
HUP0600139A2 (en) 2007-06-28
PT1891973E (pt) 2010-09-27
CA2569077C (en) 2012-12-18
ES2318498T3 (es) 2009-05-01
NO338621B1 (no) 2016-09-19
SI1763368T2 (sl) 2013-12-31
LTC1763368I2 (lt) 2016-12-27
WO2005115467A1 (en) 2005-12-08
WO2005115466A8 (en) 2007-01-04
EP2319538A2 (en) 2011-05-11
ITMI20051021A1 (it) 2005-12-01
ES2293849A1 (es) 2008-03-16
CA2533061C (en) 2008-07-08
HRP20090215T1 (hr) 2009-05-31
ES2257152B1 (es) 2007-07-01
MXPA06004124A (es) 2006-06-27
US20140148420A1 (en) 2014-05-29
US20160038470A1 (en) 2016-02-11
ME02134B (me) 2015-02-27
US20050288266A1 (en) 2005-12-29
CN1972716A (zh) 2007-05-30
DE602005013220D1 (de) 2009-04-23
EP1763368B2 (en) 2013-08-21
EP1891973B1 (en) 2010-07-21
RU2385721C2 (ru) 2010-04-10
KR20130027586A (ko) 2013-03-15
JP2008500989A (ja) 2008-01-17
US20150202213A1 (en) 2015-07-23
RU2010129940A (ru) 2012-01-27
CY1108885T1 (el) 2014-07-02
UA89181C2 (ru) 2010-01-11
US20120071452A1 (en) 2012-03-22
MXPA06013848A (es) 2007-03-01
ME02779B (me) 2010-06-30
RU2006142331A (ru) 2008-06-20
EP1765404B1 (en) 2008-12-31
US20200009117A1 (en) 2020-01-09
PL379660A1 (pl) 2006-11-13
JP2012012407A (ja) 2012-01-19
FR15C0017I2 (fr) 2015-11-13
ECSP067037A (es) 2006-12-29
ZA200609989B (en) 2007-11-28
BRPI0511662A (pt) 2008-01-02
US20140094442A1 (en) 2014-04-03
ZA200600261B (en) 2007-04-25
UA89185C2 (ru) 2010-01-11
BRPI0511660A (pt) 2008-01-02
TWI404530B (zh) 2013-08-11
RU2465902C2 (ru) 2012-11-10
SI1891973T1 (sl) 2010-11-30
CA2533061A1 (en) 2005-12-08
EP2002845A3 (en) 2009-02-25
FR15C0017I1 (ru) 2015-03-04
CN1960759A (zh) 2007-05-09
GB2419819A (en) 2006-05-10
HRP20140864T1 (hr) 2014-12-05
EP2002845A2 (en) 2008-12-17
EP2292267A2 (en) 2011-03-09
PE20060292A1 (es) 2006-04-14
ATE417627T1 (de) 2009-01-15
CA2568566A1 (en) 2005-12-08
JP5133054B2 (ja) 2013-01-30
EP2210613A1 (en) 2010-07-28
GB0526502D0 (en) 2006-02-08
EP2774622B1 (en) 2015-03-11
US20090099148A1 (en) 2009-04-16
KR101256417B1 (ko) 2013-04-22
US20050267078A1 (en) 2005-12-01
ECSP067035A (es) 2006-12-29
ES2293849B2 (es) 2009-04-16
US20130035319A1 (en) 2013-02-07
KR20070024556A (ko) 2007-03-02
UY28933A1 (es) 2005-08-31
RU2404771C2 (ru) 2010-11-27
EP2002843A2 (en) 2008-12-17
US20110021478A1 (en) 2011-01-27
CA2568566C (en) 2012-12-18
NO20065483L (no) 2006-12-22
ZA200609990B (en) 2007-12-27
ES2348680T3 (es) 2010-12-10
EP2002844A3 (en) 2009-03-04
EP2774622A1 (en) 2014-09-10
US20150306079A1 (en) 2015-10-29
US20090111785A1 (en) 2009-04-30
ZA200609987B (en) 2007-12-27
US20120059031A1 (en) 2012-03-08
CN101018566A (zh) 2007-08-15
NL300720I2 (ru) 2016-01-07
NO2015007I1 (no) 2015-03-09
US20140296197A1 (en) 2014-10-02
HK1198120A1 (en) 2015-03-13
US20180200234A1 (en) 2018-07-19
HUP0600139A3 (en) 2010-12-28
JP5538485B2 (ja) 2014-07-02
US20100056486A1 (en) 2010-03-04
EP1763368B1 (en) 2009-03-11
PE20081649A1 (es) 2008-11-28
JP2008500986A (ja) 2008-01-17
SI1763369T1 (sl) 2009-06-30
RU2006147268A (ru) 2008-07-20
JP2008500987A (ja) 2008-01-17
US20060205702A1 (en) 2006-09-14
CY1110798T1 (el) 2015-06-10
EP1763369A1 (en) 2007-03-21
JP4928258B2 (ja) 2012-05-09
AR049066A1 (es) 2006-06-21
TW200608971A (en) 2006-03-16
UA89182C2 (ru) 2010-01-11
AU2005247108A1 (en) 2005-12-08
IL179689A (en) 2012-02-29
CN1960760A (zh) 2007-05-09
ES2322280T5 (es) 2013-12-03
DK1763368T4 (da) 2013-11-04
AU2005247103A1 (en) 2005-12-08
EP2774623B1 (en) 2015-04-08
SI21784A (sl) 2005-12-31
BRPI0511669A (pt) 2008-01-02
MY142095A (en) 2010-09-15
US20050267135A1 (en) 2005-12-01
NO334337B1 (no) 2014-02-10
CN1960761A (zh) 2007-05-09
ME01670B (me) 2010-06-30
US20110021476A1 (en) 2011-01-27
HK1125573A1 (en) 2009-08-14
EP2774623A1 (en) 2014-09-10
JP2008500990A (ja) 2008-01-17
US20110021477A1 (en) 2011-01-27
US20170049756A1 (en) 2017-02-23
UA86976C2 (ru) 2009-06-10
IL179687A0 (en) 2007-05-15
HK1095757A1 (en) 2007-05-18
CY1109938T1 (el) 2014-09-10
NO20065479L (no) 2006-12-22
NO20065477L (no) 2006-12-22
RS53529B1 (sr) 2015-02-27
HRP20100489T1 (hr) 2010-10-31
GR1006045B (el) 2008-09-08
GB2419819B (en) 2007-02-21
PE20081650A1 (es) 2008-12-06
US20150080359A1 (en) 2015-03-19
IL179689A0 (en) 2007-05-15
US20120088743A1 (en) 2012-04-12
ZA200609986B (en) 2007-11-28
WO2005115466A1 (en) 2005-12-08
JP2012184272A (ja) 2012-09-27
US20080051378A1 (en) 2008-02-28
CY2015006I1 (el) 2016-06-22
DK1891973T3 (da) 2010-10-18
ECSP067038A (es) 2006-12-29
EP2002844B1 (en) 2010-12-29
US20130310354A1 (en) 2013-11-21
CY2015006I2 (el) 2016-06-22
JP5032984B2 (ja) 2012-09-26
CH696962A5 (fr) 2008-02-29
MXPA06013847A (es) 2007-03-01
CL2011000607A1 (es) 2011-08-19
UA89183C2 (ru) 2010-01-11
US20080045565A1 (en) 2008-02-21
EP2292267B1 (en) 2014-07-23
BE1016608A5 (fr) 2007-02-06
JP2006527183A (ja) 2006-11-30
PT1763368E (pt) 2009-05-14
PL1763369T3 (pl) 2009-06-30
JP5049120B2 (ja) 2012-10-17
PL1763368T5 (pl) 2014-01-31
US20090176751A1 (en) 2009-07-09
US20060154934A1 (en) 2006-07-13
FR2870744A1 (fr) 2005-12-02
KR101174677B1 (ko) 2012-08-17
CA2569077A1 (en) 2005-12-08
PT1763369E (pt) 2009-02-26
BRPI0511666A (pt) 2008-01-02
EP1765404A1 (en) 2007-03-28
NO20065478L (no) 2006-12-28
DE602005022497D1 (de) 2010-09-02
ES2322280T3 (es) 2009-06-18
HUS1500011I1 (hu) 2018-09-28
RU2006147250A (ru) 2008-07-20
EP1763368A1 (en) 2007-03-21
EP2002843A3 (en) 2009-04-08
PL1763368T3 (pl) 2009-08-31
US20120040943A1 (en) 2012-02-16
JP2008500988A (ja) 2008-01-17
NZ544539A (en) 2007-09-28
SI2292267T1 (sl) 2014-11-28
ES2257152A1 (es) 2006-07-16
NO20065476L (no) 2006-12-28
EP2292267A3 (en) 2011-06-15
HRP20090215T4 (hr) 2013-12-20
US20130252928A1 (en) 2013-09-26
US20120309726A1 (en) 2012-12-06
EP1761280A1 (en) 2007-03-14
US20070232637A1 (en) 2007-10-04
DK1763368T3 (da) 2009-05-04
NO2015007I2 (no) 2015-12-21
DK1763369T3 (da) 2009-03-16
US20100048615A1 (en) 2010-02-25
AU2005247108B2 (en) 2008-09-11
JP5107701B2 (ja) 2012-12-26
PL1765404T3 (pl) 2009-06-30
NL300720I1 (ru) 2016-01-07
JP4966192B2 (ja) 2012-07-04
ES2348558T3 (es) 2010-12-09
DK2292267T3 (da) 2014-09-15
EP1763369B1 (en) 2008-12-17
IL179687A (en) 2011-11-30
IL179684A (en) 2011-11-30
ZA200609985B (en) 2008-09-25
EP2002844A2 (en) 2008-12-17
NL1029151A1 (nl) 2005-12-05
FR2870744B1 (fr) 2006-12-08
ECSP067036A (es) 2006-12-29
LU91214B1 (fr) 2006-01-26
RS50717B (sr) 2010-06-30
HK1090306A1 (en) 2006-12-22
NZ551668A (en) 2010-06-25
RS50787B (sr) 2010-08-31
ATE474600T1 (de) 2010-08-15
PL2292267T3 (pl) 2015-03-31
IE20050366A1 (en) 2005-11-30
UA89184C2 (ru) 2010-01-11
US20120309727A1 (en) 2012-12-06
ATE424847T1 (de) 2009-03-15
BRPI0511662B1 (pt) 2019-02-19

Similar Documents

Publication Publication Date Title
RU2404771C3 (ru) Комбинации, содержащие антимускариновые средства и бета-адренергические агонисты
Williams et al. Clinical pharmacology of bronchodilator medications
RU2438660C2 (ru) Комбинация и фармацевтический препарат для лечения воспалительных и обструктивных заболеваний дыхательных путей
US9707220B2 (en) Scopolamine for the treatment of depression and anxiety
Cazzola et al. Long-acting muscarinic receptor antagonists for the treatment of respiratory disease
ES2356093T3 (es) Combinación farmacéutica que comprende 3-(3-dimetilamino-1-etil-2-metilpropil)fenol y paracetamol.
JP2008500986A5 (ru)
JP2009541443A5 (ru)
JP2017002074A (ja) 過活動膀胱を治療するためのβ−３アドレナリン受容体アゴニストおよびムスカリン受容体アンタゴニストの組み合わせ
SI2419104T1 (en) Combinations of 5-HT4 receptor agonists and acetylcholinesterase inhibitors for the treatment of cognitive disorders
RU2009133261A (ru) Комбинация антагониста мускаринового рецептора и агониста бета-2адренорецептора
RU2006146673A (ru) КОМБИНАЦИИ, СОДЕРЖАЩИЕ АНТИМУСКАРИНОВЫЕ СРЕДСТВА И β-АДРЕНЕРГИЧЕСКИЕ АГОНИСТЫ
RU2004135563A (ru) Лекарственное средство для лечения повышенной активности мочевого пузыря
Aparici et al. Pharmacological profile of AZD8871 (LAS191351), a novel inhaled dual M3 receptor antagonist/β2-adrenoceptor agonist molecule with long-lasting effects and favorable safety profile
JP2001506652A (ja) 眼の痛みを治療するためのκオピオイド・アゴニストの局所使用
CA2519679A1 (en) Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases
RU2010147881A (ru) ФАРМАЦЕВТИЧЕСКИЙ ПРОДУКТ, СОДЕРЖАЩИЙ АНТАГОНИСТ МУСКАРИНОВОГО РЕЦЕПТОРА И АГОНИСТ β2-АДРЕНОРЕЦЕПТОРА
RU2011105463A (ru) ФАРМАЦЕВТИЧЕСКИЙ ПРОДУКТ, СОДЕРЖАЩИЙ АНТАГОНИСТ МУСКАРИНОВОГО РЕЦЕПТОРА И АГОНИСТ β2-АДРЕНОРЕЦЕПТОРА
KR20160067193A (ko) 주의력 및 인지 장애, 및 신경 퇴행성 장애와 관련된 치매 치료용 신규 치료제
KR20100040294A (ko) 전립선 비대에 수반되는 하부 요로 증상의 개선용 의약 조성물
CN104144688B (zh) p75受体拮抗剂的治疗用途
RU2011105460A (ru) Фармацевтический продукт, содержащий антагонист мускаринового рецептора и второй активный ингредиент
Lu et al. Prevention of penehyclidine on postoperative nausea and vomiting in patients with thyroid surgery: a prospective, randomized, double-blinded comparison
JP2007509865A (ja) 神経障害の治療における選択的オピエート受容体調節物質の使用
Waldvogel μ-Agonisten

Legal Events

Date Code Title Description
ND4A Extension of patent duration

Effective date: 20180312